Clinical Trials Browser

NETWORK × Multiple Myeloma × Doxorubicin × Clear all

NCT00002878 2023-06-15

Combination Chemotherapy With or Without PSC 833 in Treating Patients With Relapsed or Refractory Multiple Myeloma

Phase 3 Completed

Multiple Myeloma, Neoplasms, Plasma Cell

NCT00002548 2015-03-06

SWOG-9321 Melphalan, TBI, and Transplant vs Combo Chemo in Untreated Myeloma

Phase 3 Completed

Multiple Myeloma

NCT01055301 2015-03-06

S0833, Bortezomib, Thalidomide, Lenalidomide, Combination Chemotherapy, and Autologous Stem Cell Transplant in Treating Patients With Newly Diagnosed Multiple Myeloma

Phase 2 Withdrawn

Multiple Myeloma

NCT00814541 2014-12-31

PAD. ICORG 05-01, V11

Phase 2 Completed

Multiple Myeloma, Neoplasms, Plasma Cell

NCT00002657 2013-01-24

SWOG-9239 Reduction of Immunosuppression Plus Interferon Alfa and Combination Chemotherapy in Treating Patients With Malignant Tumors That Develop After Organ Transplant

Phase 2 Completed

LymphoidOther hematologic neoplasmPlasma cell

Burkitt Lymphoma, Lymphoma, Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Waldenstrom Macroglobulinemia, Multiple Myeloma, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, Large-Cell, Immunoblastic, Lymphoma, Large B-Cell, Diffuse, Lymphoma, B-Cell, Marginal Zone, Neoplasms, Plasma Cell